Jared Weiss, MD

Cetuximab

Durvalumab

astrazeneca, unc-lineberger-comprehensive-cancer-center

phase_2phase_4

Paclitaxel

Nab-paclitaxel

Cisplatin

Transoral Surgery

1 trial

Lapatinib

1 trial

Durvalumab Long-Term Safety and Efficacy Study

+8 more interventions

16 unique interventions4 categories

Analytics

Trial Phases

Phase 26

Phase 41

Trial Status

Completed5

Terminated1

Other1

Role Distribution

Principal Investigator7

PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT04078152Phase 4Completed

Solid Tumor

PrincipalinvestigatorStart date: 2019-09-05

NCT03174275Phase 2Active Not Recruiting

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous CellEsophageal CancerLarynx Cancer+3 more

PrincipalinvestigatorStart date: 2017-12-19

NCT02684461Phase 2Completed

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

Non Small Cell Lung Cancer

PrincipalinvestigatorStart date: 2016-09-13

NCT02124707Phase 2Completed

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Head and Neck CancerSquamous Cell Carcinoma of the Head and Neck

PrincipalinvestigatorStart date: 2014-06-16

NCT01612351Phase 2Completed

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Head and Neck CancerSquamous Cell Carcinoma of the Head and Neck

PrincipalinvestigatorStart date: 2012-06-01

NCT01412229Phase 2Completed

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

Principalinvestigator

NCT02276560Phase 2Terminated

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Stage IIIA Non-Small Cell Lung Cancer

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Cancer of Head and Neck3 Squamous Cell Carcinoma of Head and Neck2 Carcinoma, Squamous Cell1 Cancer of Esophagus1 Cancer of Larynx1 Cancer of Lip1 Carcinoma, Non-Small-Cell Lung1 Cancer of Mouth1

Affiliations

University of North Carolina, Chapel Hill

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

21 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungCancer of EsophagusCancer of Head and Neck+1 more

Similarity Score11%

Michael B Gill

Power Life Sciences Inc.

105 trials

Shared therapeutic areas:

Cancer of EsophagusCancer of Head and NeckCarcinoma, Non-Small-Cell Lung+1 more

Similarity Score11%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

13 trials

Shared therapeutic areas:

Cancer of EsophagusCancer of Head and NeckCarcinoma, Non-Small-Cell Lung

Similarity Score8%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

32 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungCancer of Oropharnyx

Carcinoma, Non-Small-Cell LungSolid Tumor

You Lu, MD

West China Hospital

18 trials

Shared therapeutic areas:

Worked with same sponsors:

AstraZeneca

Cancer of EsophagusCancer of Head and Neck

John D. Hainsworth, MD

SCRI Development Innovations, LLC

26 trials

Shared therapeutic areas:

Worked with same sponsors:

AstraZenecaGlaxoSmithKline

Carcinoma, Non-Small-Cell LungCancer of Mouth

Urielle Desalbres

Assistance Publique Hôpitaux de Marseille

71 trials

Shared therapeutic areas:

Cancer of EsophagusCancer of Head and Neck

Aminah Jatoi, MD

Mayo Clinic

29 trials

Shared therapeutic areas:

Solid TumorCancer of Esophagus

Lin Shen, MD

Peking University Cancer Hospital & Institute

20 trials

Shared therapeutic areas:

Solid TumorCarcinoma, Non-Small-Cell Lung

Rahul Aggarwal, MD

University of California, San Francisco

22 trials

Shared therapeutic areas:

Worked with same sponsors:

AstraZenecaMerck Sharp & Dohme LLC